Advanced Medical Isotope Corp. (OTCMKTS:ADMD) was not one of the buzzing stocks early in this year. It happened to get all the attention after some paid campaigns were launched to push the stock up on the chart.
Advanced Medical Isotope with a current market capitalization of $11.03 million is perfect example of a noteworthy imminent radiotherapy treatment provider firm that is suited for aggressive investors. It is a late-stage development entity engaged mainly in the advancement of medical isotopes and brachytherapy devices for therapeutic and diagnostic applications, with main focus on ‘yttrium-90 brachytherapy’ therapies.
The worldwide market for brachytherapy was computed at $680,000,000 in 2013 and is projected to reach nearly $2.4 billion by 2030. With only few firms, the opportunity for Advanced Medical seems to be massive. Brachytherapy can be defined as a form of treatment that utilizes a radiation source usually wrapped in a small holder named as an implant. It is placed inside or close to the tumor. It enables a higher quantity of radiation in a smaller region than might be achievable with external radiation treatment.
Advanced Medical Isotope certainly has several red flags surrounding it. However, the company has managed to post a remarkable gains in this month. The first thing that investors ever look for is the financial performance of the company. As per the last quarterly report, the company posted cash of $7,000. The current liabilities came at $8,800,000 while current assets were just $42,000. Advanced Medical reported revenue of $12,000 on net loss of $2.5 million.
These financials look pretty dismal, and they are just one of the red flags surrounding company. The company’s authorized share was 2 billion at the end of this period and since then it has taken drastic steps in further dilution of the stock.